Evidence map›Paper›PMID 40927762›Full record

ArticleMolecular therapy. Methods & clinical development2025

Preclinical studies of an AAV8-CYP4V2 gene therapy VGR-R01 for the treatment of Bietti crystalline dystrophy.

Wenjing Luo, Lu Guo, Liang Lu, Nan Huang, Yezheng Tao, Yufei Zhang, Yanrong Cao, Shin-Shay Tian, Xiaoping Zhao, Xi Zhu

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenjing LuoShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Lu GuoShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Liang LuShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Nan HuangShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Yezheng TaoShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Yufei ZhangShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Yanrong CaoShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Shin-Shay TianShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Xiaoping ZhaoShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.
Xi ZhuShanghai Vitalgen BioPharma Co., Ltd., Shanghai 201210, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bietti crystalline dystrophy (BCD) is an autosomal recessive disorder caused by loss-of-function mutations in the

Indexed as

AAVBCDCYP4V2preclinical studysubretinal injection

Identifiers

PMID40927762
PMCPMC12415973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.